Cargando…

Investigation of the prevalence and clinical implications of ERBB2 exon 16 skipping mutations in Chinese pan-cancer patients

BACKGROUND: Although rare, ERBB2 exon 16 skipping mutations (ERBB2ΔEx16) have been implicated in resistance to anti-HER2 and anti-EGFR targeted agents. Our study investigated the prevalence and clinical significance of ERBB2ΔEx16 in Chinese pan-cancer patients. METHODS: We retrospectively screened 4...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shang, Yanhong, Mo, Jianming, Huo, Ran, Li, Xiaofang, Fang, Guotao, Wei, Zichun, Gu, Guomin, Zhu, Xiaodan, Zhang, Chan, Liu, Chunling, Yan, Dong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9859631/ https://www.ncbi.nlm.nih.gov/pubmed/36686783 http://dx.doi.org/10.3389/fonc.2022.1064598

Ejemplares similares

Clinical significance of ERBB2 exon 16 skipping: analysis of a real-world retrospective observational cohort study
por: Shi, Lei, et al.
Publicado: (2020)

Mesenchymal-Epithelial Transition Exon 14 Skipping Mutation and Amplification in 5,008 Patients With Lung Cancer
por: Song, Yaolin, et al.
Publicado: (2021)

MMP11 is associated with the immune response and immune microenvironment in EGFR-mutant lung adenocarcinoma
por: Bai, Lu, et al.
Publicado: (2023)

ExonSkipDB: functional annotation of exon skipping event in human
por: Kim, Pora, et al.
Publicado: (2020)

Exploring the Significance of the Exon 4-Skipping Isoform of the ZNF217 Oncogene in Breast Cancer
por: Bellanger, Aurélie, et al.
Publicado: (2021)

Exon skipping for DMD
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2012)

Natural Exon Skipping Sets the Stage for Exon Skipping as Therapy for Dystrophic Epidermolysis Bullosa
por: Bremer, Jeroen, et al.
Publicado: (2019)

PD-L1 expression, tumor mutational burden, and immune cell infiltration in non-small cell lung cancer patients with epithelial growth factor receptor mutations
por: Ma, Tiantian, et al.
Publicado: (2022)

Integrative genomic analysis of drug resistance in MET exon 14 skipping lung cancer using patient-derived xenograft models
por: Xu, Yunhua, et al.
Publicado: (2022)

Therapeutic exon skipping for dysferlinopathies?
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2010)

Survival outcomes and prognostic factors of lung cancer patients with the MET exon 14 skipping mutation: A single-center real-world study
por: Gow, Chien-Hung, et al.
Publicado: (2023)

Exon-Skipping in Duchenne Muscular Dystrophy
por: Takeda, Shin’ichi, et al.
Publicado: (2021)

Targeted Exon Skipping to Correct Exon Duplications in the Dystrophin Gene
por: Greer, Kane L, et al.
Publicado: (2014)

A compatible exon-exon junction database for the identification of exon skipping events using tandem mass spectrum data
por: Mo, Fan, et al.
Publicado: (2008)

Use of savolitinib as neoadjuvant therapy for non–small cell lung cancer patient with MET exon 14 skipping alterations: A case report
por: Zhang, Yu, et al.
Publicado: (2022)

Dramatic response to neoadjuvant savolitinib in marginally resectable lung adenocarcinoma with MET exon 14 skipping mutation: A case report and literature review
por: Tian, Jiangfang, et al.
Publicado: (2022)

Insecticide resistance mediated by an exon skipping event
por: Berger, Madeleine, et al.
Publicado: (2016)

Therapeutic Prospects of Exon Skipping for Epidermolysis Bullosa
por: Vermeer, Franciscus C., et al.
Publicado: (2021)

Proteopathy Linked to Exon-Skipping Isoform of RGR-Opsin Contributes to the Pathogenesis of Age-Related Macular Degeneration
por: Ren, Chi, et al.
Publicado: (2023)

EGFR and ERBB2 exon 20 insertion/duplication in advanced non–small cell lung cancer: genomic profiling and clinicopathologic features
por: Sompallae, Ramakrishna R., et al.
Publicado: (2023)

Prediction of alternatively skipped exons and splicing enhancers from exon junction arrays
por: Kechris, Katerina, et al.
Publicado: (2008)

Classifying Included and Excluded Exons in Exon Skipping Event Using Histone Modifications
por: Chen, Wei, et al.
Publicado: (2018)

A Genotype-Phenotype Correlation Study of Exon Skip-Equivalent In-Frame Deletions and Exon Skip-Amenable Out-of-Frame Deletions across the DMD Gene to Simulate the Effects of Exon-Skipping Therapies: A Meta-Analysis
por: Anwar, Saeed, et al.
Publicado: (2021)

Co-Occurring Alterations of ERBB2 Exon 20 Insertion in Non-Small Cell Lung Cancer (NSCLC) and the Potential Indicator of Response to Afatinib
por: Yuan, Bo, et al.
Publicado: (2020)

Neoadjuvant Savolitinib targeted therapy stage IIIA-N2 primary lung adenocarcinoma harboring MET Exon 14 skipping mutation: A case report
por: Fu, Meng, et al.
Publicado: (2022)

Variants Affecting Exon Skipping Contribute to Complex Traits
por: Lee, Younghee, et al.
Publicado: (2012)

Multiple exon skipping strategies to by-pass dystrophin mutations
por: Adkin, Carl F., et al.
Publicado: (2012)

Elusive sources of variability of dystrophin rescue by exon skipping
por: Vila, Maria Candida, et al.
Publicado: (2015)

Skipping Multiple Exons to Treat DMD—Promises and Challenges
por: Aslesh, Tejal, et al.
Publicado: (2018)

Combinatorial Pattern of Histone Modifications in Exon Skipping Event
por: Chen, Wei, et al.
Publicado: (2019)

Exon-skipping antisense oligonucleotides for cystic fibrosis therapy
por: Kim, Young Jin, et al.
Publicado: (2022)

Inhibition of Melanosome Transport by Inducing Exon Skipping in Melanophilin
por: Kim, Jin Young, et al.
Publicado: (2023)

Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study
por: Liu, Li, et al.
Publicado: (2021)

Single Exon Skipping Can Address a Multi-Exon Duplication in the Dystrophin Gene
por: Greer, Kane, et al.
Publicado: (2020)

ERBB2D16 Expression in HER2 Positive Gastric Cancer Is Associated With Resistance to Trastuzumab
por: Wang, Shuo, et al.
Publicado: (2022)

Biomarker Testing Patterns and Treatment Outcomes in Patients With Advanced Non-Small Cell Lung Cancer and MET Exon 14 Skipping Mutations: A Descriptive Analysis From the US
por: Asad Zadeh Vosta Kolaei, Fatemeh, et al.
Publicado: (2022)

Case report: Success of tepotinib therapy in overcoming resistance to osimertinib in a patient with EGFR-mutant lung adenocarcinoma with a potential acquired MET exon 14 skipping mutation
por: Takamori, Shinkichi, et al.
Publicado: (2022)

Exon skipping-rich transcriptomes of animals reflect the significance of exon-shuffling in metazoan proteome evolution
por: Patthy, Laszlo
Publicado: (2019)

A spliceosomal twin intron (stwintron) participates in both exon skipping and evolutionary exon loss
por: Kavalecz, Napsugár, et al.
Publicado: (2019)

Targeted exon skipping of NF1 exon 17 as a therapeutic for neurofibromatosis type I
por: Leier, André, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_chc7oefaiug2v5nq3324om9qig